Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $186.00.

A number of analysts have recently issued reports on RGEN shares. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. TD Cowen started coverage on Repligen in a research note on Monday. They issued a “buy” rating and a $200.00 price target on the stock. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Finally, HC Wainwright lowered their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd.

Institutional Investors Weigh In On Repligen

Large investors have recently bought and sold shares of the stock. Signaturefd LLC increased its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. UMB Bank n.a. increased its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. increased its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. Resources Management Corp CT ADV purchased a new stake in Repligen during the 3rd quarter worth about $37,000. Finally, Quarry LP increased its holdings in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 1.4 %

Repligen stock opened at $153.86 on Thursday. The stock has a market capitalization of $8.62 billion, a PE ratio of -415.83, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The business has a 50 day simple moving average of $155.37 and a 200-day simple moving average of $148.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 earnings per share. On average, analysts anticipate that Repligen will post 1.54 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.